In the present work we assessed mRNA expression and serum protein levels of IL-1β in newly diagnosed T2D individuals with hyperglycemia and after 6 and 12 months of treatment, when they achieved their glycemic target control. This evidence concerns the gene IL1B and type 2 diabetes mellitus.